Tempus AI

Tempus AI Net Tangible Assets

The Net Tangible Assets of Tempus AI (TEM) as of Nov 20, 2026 is -334.14 M USD. In the previous year, Net Tangible Assets was -28.72 M USD — a change of 1,063.43% (lower).

Net Tangible Assets

-334.14 MUSD

YoY

1,063.43%

Last updated:

Net Tangible Assets of Tempus AI is 2025 -334.14 M USD. Net Tangible Assets of Tempus AI was 2024 -28.72 M USD. It decreases by 1,063.43% lower compared to the previous year.

The Tempus AI Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2019
-311.73 M USD
Jan 1, 2020
-573.44 M USD
Jan 1, 2021
-860.76 M USD
Jan 1, 2022
-1.22 B USD
Jan 1, 2023
-1.48 B USD
Jan 1, 2024
-28.72 M USD
Jan 1, 2025
-334.14 M USD
The Tempus AI Net Tangible Assets history
YEARNet Tangible AssetsYoY
-334.14 MUSD+1,063.43%
-28.72 MUSD-98.06%
-1.48 BUSD+21.16%
-1.22 BUSD+41.67%
-860.76 MUSD+50.11%
-573.44 MUSD+83.95%
-311.73 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Net Tangible Assets of Tempus AI is -334.14 M USD in 2025.

Net Tangible Assets of Tempus AI changed from -28.72 M USD to -334.14 M USD, representing a 1,063.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tempus AI

All Key Metrics — Tempus AI